Collegium Pharmaceutical (COLL) PT Lowered to $27 at Truist Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
Collegium Pharmaceutical (COLL) PT Lowered to $26 at Needham & Company
November 5, 2021 7:43 AM EDTNeedham & Company analyst Serge Belanger lowered the price target on Collegium Pharmaceutical (NASDAQ: COLL) to $26.00 (from $32.00) while maintaining a Buy rating.
The analyst commented, "Xtampza struggled in 3Q21 with sales of $30.0MM (-9%Q/Q and -7%Y/Y) due to... More
